Menu
Menu
21A available now! 21B will be available in October 2024.
Expiration dates to claim credit:
21A: April 30, 2025
21B: October 31, 2025
Test your knowledge of anesthesia fundamentals!
Developed by practicing anesthesiologists, each issue of ACE... Read More +
The American Society of Anesthesiologists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Anesthesiologists designates this enduring material for a maximum of 60 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For ACE 21A, up to 2 credits contribute to the patient safety CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology® (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website for a list of all MOCA 2.0 requirements. Patient safety content for the 21B issue will be announced in the fall of 2024.
Maintenance of Certification in Anesthesiology® and MOCA® are registered certification marks of the American Board of Anesthesiology®. MOCA 2.0® is a trademark of the American Board of Anesthesiology®.
Credit for Canadian MOC Participants: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program. Visit the ACCME website for more information.
For information on other accreditations, contact ASA Member Services at (847) 825-5586.
Access ACE 2024 - Issue 21A Electronic
Access ACE 2024 - Issue 21A Booklet
Issue 21B will be available in October 2024.
To access all of your courses, log into My Courses.
After successfully completing this activity, the learner will be able to
Bhargavi Gali, MD, MHA, Co-Editor-in-Chief
Rochester, Minnesota
Stacy L. Jones, MD, MHA, FASA, Co-Editor-in-Chief
Austin, Texas
Anuj K. Aggarwal, MD
Stanford, California
Shamsuddin Akhtar, MD
New Haven, Connecticut
Vaibhav Bora, MBBS, FASE, FCCM, FCCP
Augusta, Georgia
Russell K. McAllister, MD, FASA
Temple, Texas
Shobana Rajan, MD, FASA
Cleveland, Ohio
Sara Robertson, MD, FASA
Madison, Mississippi
Ahmed Shalabi, MBBCh, MSc, FCAI
Los Angeles, California
Kofi B. Vandyck, MD
Oklahoma City, Oklahoma
Christine T. Vo, MD, FASA
Oklahoma City, Oklahoma
Maheen A. Wardak, MD
Houston, Texas
ASA Staff: Ginger Clark, Managing Editor
Resolution of Conflicts of Interest: ASA remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of ASA to eliminate all situations of potential conflict of interest, but rather to enable those who are working with ASA to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the educational activity course director/chair to ensure that such situations are properly evaluated and, if necessary, resolved. ASA educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all ASA activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.
Ineligible companies are those not eligible to be accredited by the Accreditation Council for Continuing Medical Education because the primary business of these companies is producing, marketing, selling, reselling, or distributing health care products used by or on patients. The faculty and staff below have reported the following financial relationships with ineligible companies:
Ginger Clark
Merck: Stock (self)
Organon & Co: Stock (self)
Bhargavi Gali, MD
Takeda Pharmaceuticals: Independent contractor—consultant (self)
All disclosed financial relationships have been mitigated. All other faculty, planners, and staff have reported no financial relationships with ineligible companies.
